Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

NASDAQ:SNSE - Nasdaq - US81728A1088 - Common Stock - Currency: USD

0.4724  -0.01 (-1.58%)

Fundamental Rating

2

Overall SNSE gets a fundamental rating of 2 out of 10. We evaluated SNSE against 572 industry peers in the Biotechnology industry. SNSE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNSE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SNSE has reported negative net income.
SNSE had a negative operating cash flow in the past year.
SNSE had negative earnings in each of the past 5 years.
In the past 5 years SNSE always reported negative operating cash flow.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

SNSE has a Return On Assets (-55.96%) which is in line with its industry peers.
SNSE has a Return On Equity (-65.10%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.96%
ROE -65.1%
ROIC N/A
ROA(3y)-36.97%
ROA(5y)-383.39%
ROE(3y)-41.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNSE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

SNSE has less shares outstanding than it did 1 year ago.
The number of shares outstanding for SNSE has been reduced compared to 5 years ago.
The debt/assets ratio for SNSE is higher compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.77, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
SNSE's Altman-Z score of -6.77 is on the low side compared to the rest of the industry. SNSE is outperformed by 68.67% of its industry peers.
SNSE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, SNSE perfoms like the industry average, outperforming 44.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.77
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

SNSE has a Current Ratio of 8.84. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.84, SNSE is in the better half of the industry, outperforming 75.58% of the companies in the same industry.
SNSE has a Quick Ratio of 8.84. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
SNSE's Quick ratio of 8.84 is fine compared to the rest of the industry. SNSE outperforms 76.11% of its industry peers.
Industry RankSector Rank
Current Ratio 8.84
Quick Ratio 8.84
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.85% over the past year.
EPS 1Y (TTM)9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNSE will show a small growth in Earnings Per Share. The EPS will grow by 5.75% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.29%
EPS Next 2Y15.19%
EPS Next 3Y12.77%
EPS Next 5Y5.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as SNSE's earnings are expected to grow with 12.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.19%
EPS Next 3Y12.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (2/11/2025, 11:53:15 AM)

0.4724

-0.01 (-1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-06 2025-03-06/amc
Inst Owners8.45%
Inst Owner Change-51.96%
Ins Owners2.24%
Ins Owner Change0%
Market Cap11.88M
Analysts89.09
Price Target4.21 (791.19%)
Short Float %4.58%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.93%
Min EPS beat(2)4.85%
Max EPS beat(2)9.02%
EPS beat(4)3
Avg EPS beat(4)1.05%
Min EPS beat(4)-14.08%
Max EPS beat(4)9.02%
EPS beat(8)7
Avg EPS beat(8)5.29%
EPS beat(12)9
Avg EPS beat(12)3.57%
EPS beat(16)10
Avg EPS beat(16)-1.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.94%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)1.48%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-2.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.96%
ROE -65.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.97%
ROA(5y)-383.39%
ROE(3y)-41.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.04%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.84
Quick Ratio 8.84
Altman-Z -6.77
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)110.41%
Cap/Depr(5y)195.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
EPS Next Y4.29%
EPS Next 2Y15.19%
EPS Next 3Y12.77%
EPS Next 5Y5.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y1.26%
EBIT Next 5YN/A
FCF growth 1Y34.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.9%
OCF growth 3YN/A
OCF growth 5YN/A